Rebecca Booth, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 40 1st St Se, Waukon, IA 52172 Phone: 563-568-3411 |
Mrs. Laurel Ann Hagensick, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 40 1st St Se, Waukon, IA 52172 Phone: 563-568-3411 Fax: 563-568-5699 |
Dennis Clarence Montet, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1650 Allamakee St Nw, Waukon, IA 52172 Phone: 563-568-2176 Fax: 563-568-2184 |
Sharon Debra Erickson, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 391 Heritage Dr, Waukon, IA 52172 Phone: 563-568-2572 |
Austin Troendle, PT, DPT, ATC, LAT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 40 1st St Se, Waukon, IA 52172 Phone: 563-568-9897 |
Alana Jo Gavin Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 40 1st St Se, Waukon, IA 52172 Phone: 563-568-5528 |
Amy G Robinson, P.T. Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 40 1st St Se, Waukon, IA 52172 Phone: 563-568-3411 |
Abigail Daniel Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 40 1st St Se, Waukon, IA 52172 Phone: 563-568-5528 |
News Archive
Researchers are developing low-cost technologies to tackle indoor air pollution that is a growing menace. A new generation of electrostatic filters can capture even the smallest particles of household pollutants, using a little amount of energy.
Researchers at Cedars-Sinai Medical Center have announced the start of the EASE (Exhale Airway Stents for Emphysema) Trial, an international, multi-center clinical trial to explore an investigational treatment that may offer a new, minimally-invasive option for those suffering with advanced widespread emphysema.
LMBRI LLC and Lipopharma Therapeutics SL today announced collaboration aimed at transforming cancer drug development and improving patient outcomes. Lipopharma developed new assessment approaches, methods and technologies for developing cancer therapeutics and diagnostics using their proprietary design of structure-based molecules that regulate the structure and functions of the membrane lipids, instead targeting cellular proteins, called "Membrane Lipid-Therapy".
Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company focused on the global immunology market, today announced the initiation of its Phase 2 trial evaluating voclosporin ophthalmic solution (VOS) for the treatment of dry eye syndrome (DES).
› Verified 8 days ago